The U.S. Supreme Court issued a unanimous ruling in Hikma’s favor in a “skinny label” patent case involving Amarin’s Vascepa, clearing the pathway for generic competition under indication-specific labeling that does not infringe protected uses. The 9–0 decision reverses a lower-court finding and reaffirms that generic marketing choices tied to label scope can matter. Meanwhile, Takeda disclosed a major antitrust-driven financial impact after a federal jury in Boston found it liable in a pay-for-delay lawsuit tied to Amitiza. Takeda recorded a provision for legal proceedings that management tied to a liability that could reach about $2.5 billion when automatically tripled under antitrust law. For the industry, the combination of Supreme Court patent clarity and escalating antitrust exposure underscores how legal and labeling frameworks continue to define effective market timing for competitors. It also raises the stakes for settlement strategy and patent-positioning in branded-to-generic transitions.